{"Clinical Trial ID": "NCT01007942", "Intervention": ["INTERVENTION 1:", "Everolimus + Vinorelbine + Trastuzumab", "- Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 per week) + intravenous trastuzumab (2 mg/kg per week after a loading dose of 4 mg/kg on day 1 of cycle 1 only)", "INTERVENTION 2:", "Placebo + Vinorelbine + Trastuzumab", "- oral placebo and intravenous vinorelbine (25 mg/m2 per week) + intravenous trastuzumab (2 mg/kg per week after a loading dose of 4 mg/kg on day 1 of cycle 1 only)"], "Eligibility": ["Incorporation criteria:", "Invasive invasive carcinoma confirmed histologically or cytologically with locally recurrent or radiological signs of metastatic disease. Local recurrent disease should not be susceptible to resection with curative intent.", "HER2+ is defined as IHC 3+ coloration or positive in situ hybridization", "Patients with trastuzumab resistance", "\u2022 Prior taxan therapy", "Patients with an ECOG performance status of 0 to 2", "* Patients with a measurable disease according to the RECIST criteria", "Sexually active premenopausal women should use adequate contraceptive measures, excluding estrogen containing contraceptives, during their study;", "Patients should meet the laboratory criteria defined in the study within 21 days prior to randomization.", "- Exclusion criteria:", "Previous mTOR inhibitors or vinca alkaloid agents for cancer treatment", "More than three previous chemotherapy lines for advanced disease.", "The previously treated asymptomatic CNS metastases are allowed provided that the last treatment of CNS metastases is completed >8 weeks prior to randomization.", "Inadequate gastrointestinal function (GI) or gastrointestinal disease that may significantly affect oral absorption of everolimus", "- Grade 2 peripheral neuropathy at randomisation", "\u2022 Active heart disease", "\u2022 History of cardiac dysfunction", "Any malignancy within 5 years prior to randomisation, with the exception of in situ cervix carcinoma, basal or squamous carcinoma or non-melanoma skin cancer", "\u2022 Known hypersensitivity to any study medicinal product", "Breast-feeding or pregnancy"], "Results": ["Performance measures:", "\u00b7 A progression-free survival (PFS) per surveyor Evaluation", "The PFS was defined as the time between the date of randomization and the date of the first progression of the radiologically documented tumour or death of any cause. The primary analysis of the PFS was performed when 415 events were reached. The progression is defined using the criteria for assessing response in solid tumours (RECIST v1.0), such as a 20% increase in the sum of the longest diameter of the target lesions, or a measurable increase in non-target injury, or the appearance of new lesions.", "Timeline: Every 6 weeks until disease progression or death that has never occurred up to about 41 months", "Results 1:", "Title of the arm/group: Everolimus + Vinorelbine + Trastuzumab", "Description of the arm/group: Oral Everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 per week) + intravenous trastuzumab (2 mg/kg per week after a loading dose of 4 mg/kg on the first day of the cycle)", "Total number of participants analysed: 284", "Median (95% confidence interval)", "Unit of measure: month 7,00 (6,74 to 8,18)", "Results 2:", "Title of the arm/group: Placebo + Vinorelbine + Trastuzumab", "Description of the arm/group: daily oral placebo + intravenous vinorelbine (25 mg/m2 per week) + intravenous trastuzumab (2 mg/kg per week after a loading dose of 4 mg/kg on day 1 of cycle 1 only)", "Total number of participants analysed: 285", "Median (95% confidence interval)", "Unit of measure: month 5.78 (5.49 to 6.90)"], "Adverse Events": ["Undesirable Events 1:", "Total: 122/280 (43.57 per cent)", "Agranulocytosis 0/280 (0.00 %)", "Anemia 10/280 (3.57%)", "Febrile neutropenia 30/280 (10.71%)", "Immune thrombocytopenia purpura 1/280 (0.36%)", "Leukopenia 3/280 (1.07%)", "Neutropenia 12/280 (4.29%)", "Thrombocytopenia 4/280 (1.43%)", "- Acute myocardial infarction 1/280 (0.36%)", "- Heart failure 1/280 (0.36%)", "Cataract 2/280 (0.71%)", "Adverse Events 2:", "Total: 58/282 (20.57 per cent)", "Agranulocytosis 1/282 (0.35%)", "Anemia 2/282 (0.7%)", "- Febrile neutropenia 4/282 (1.42%)", "Immune thrombocytopenia purpura 0/282 (0.00 %)", "- Leucopenia 0/282 (0.00 %)", "Neutropenia 3/282 (1.06%)", "Thrombocytopenia 1/282 (0.35%)", "- Acute myocardial infarction 0/282 (0.00 %)", "- Heart failure 0/282 (0.00 %)", "Cataract 1/282 (0.35%)", "Subcapsular cataract 1/282 (0.35%)"]}